Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 appendix a supplementary data to this article can be found online at https://doi org/10 1016/j euros2023 10 007 ."

"

 Financial disclosures: Lars Dyrskjøt certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Anders Neijber and Kristine Young-Halvorsen are employees of and hold stock or stock options in Photocure ASA. Jørgen Bjerggaard Jensen is an advisory board member for Ferring, Roche, Cepheid, Urotech, Olympus, AMBU, Janssen; Speaker: Medac, Olympus, Intuitive Surgery, and Photocure ASA; and is involved in research collaborations with Medac, Photocure ASA, Roche, Ferring, Karl Storz, Olympus, Intuitive Surgery, Astellas, Cepheid, Nucleix, Urotech, Pfizer, and AstraZeneca. Lars Dyrskjøt has sponsored research agreements with Natera, C2i Genomics, AstraZeneca, Photocure, and Ferring; has an advisory/consulting role at Ferring, MSD, and UroGen; has received speaker honoraria from AstraZeneca, Pfizer, and Roche; and is a board member for BioXpedia. The remaining authors have nothing to disclose. Financial disclosures:"

"

Financial disclosures: Lars Dyrskjøt certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Anders Neijber and Kristine Young-Halvorsen are employees of and hold stock or stock options in Photocure ASA. Jørgen Bjerggaard Jensen is an advisory board member for Ferring, Roche, Cepheid, Urotech, Olympus, AMBU, Janssen; Speaker: Medac, Olympus, Intuitive Surgery, and Photocure ASA; and is involved in research collaborations with Medac, Photocure ASA, Roche, Ferring, Karl Storz, Olympus, Intuitive Surgery, Astellas, Cepheid, Nucleix, Urotech, Pfizer, and AstraZeneca. Lars Dyrskjøt has sponsored research agreements with Natera, C2i Genomics, AstraZeneca, Photocure, and Ferring; has an advisory/consulting role at Ferring, MSD, and UroGen; has received speaker honoraria from AstraZeneca, Pfizer, and Roche; and is a board member for BioXpedia. The remaining authors have nothing to disclose. 

Funding/Support and role of the sponsor: This work was funded by a grant from Photocure ASA to Lars Dyrskjøt. The sponsor played a role in the design and conduct of the study; interpretation of the data; and review and approval of the manuscript."